Fibromyalgia After an Accident: Medications, Causation, and the Pharmacy Lien Record

James Wong — Founder & Pharmacist, LienScripts | February 17, 2026 | 8 min read

Post-traumatic fibromyalgia is a recognized complication of peripheral injury and central sensitization. Learn about FDA-approved medications, off-label options, why insurers dispute the diagnosis, and how the pharmacy record establishes a consistent clinical narrative.

When Pain Outlasts the Injury: Post-Traumatic Fibromyalgia

For many personal injury claimants, the expected recovery arc never arrives. Fractures heal, surgical wounds close, soft tissue inflammation subsides — yet a diffuse, widespread pain syndrome persists and often intensifies over the months following the accident. When that syndrome meets specific diagnostic criteria and cannot be explained by another structural condition, the diagnosis is fibromyalgia.

Post-traumatic fibromyalgia — fibromyalgia triggered or unmasked by a peripheral injury — represents one of the more complex and contested diagnoses in personal injury medicine. Insurers and defense counsel challenge it aggressively because it lacks visible radiographic findings, relies heavily on patient-reported symptoms, and involves a causation theory (central sensitization after peripheral trauma) that requires expert explanation. But the science supporting this mechanism is well-established, and the medication record generated under a pharmacy lien provides objective, third-party documentation of an escalating treatment need — exactly the kind of evidence that supports the claimant's narrative.

The Central Sensitization Mechanism

The biological mechanism linking peripheral injury to fibromyalgia development is central sensitization. After a significant traumatic injury — particularly one involving musculoskeletal damage, nerve injury, or chronic pain — the central nervous system undergoes maladaptive changes that amplify pain signals. The spinal dorsal horn neurons become hyperexcitable, the descending pain inhibitory pathways weaken, and the brain's pain processing regions develop abnormal activity patterns.

The result is that stimuli that would not normally be painful become painful (allodynia), and ordinarily painful stimuli produce disproportionate pain responses (hyperalgesia). Unlike the localized pain of a structural injury, this sensitized pain is diffuse, migratory, and resistant to standard analgesics.

Research supports the trauma-to-fibromyalgia pathway. A 2006 study published in Arthritis & Rheumatism found that individuals involved in neck injury events had a significantly higher rate of developing fibromyalgia compared to matched controls with leg fractures, suggesting that the mechanism involves more than physical damage alone.

[!SOURCE] Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. "Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury." Arthritis & Rheumatism. 1997;40(3):446-452. PMID: 9082932.

Diagnostic Criteria: The 2010/2016 ACR Framework

The American College of Rheumatology revised fibromyalgia diagnostic criteria in 2010 and updated them in 2016. The current criteria no longer require a tender point examination. Instead, diagnosis requires:

Widespread Pain Index (WPI): A score of 7 or higher (out of 19 body regions assessed) combined with a Symptom Severity Scale (SSS) score of 5 or higher — OR a WPI of 4–6 with an SSS score of 9 or higher.

Symptom Severity Scale components:

• Fatigue
• Waking unrefreshed
• Cognitive symptoms ("fibro fog")
• Somatic symptoms (headache, pain or cramps in the lower abdomen, depression)

Duration: Symptoms present at a similar level for at least 3 months.

Exclusion: The pain is not better explained by another diagnosis.

This diagnostic framework matters for personal injury purposes because the timeline — symptoms present for at least 3 months — creates a documentable window. Pharmacy records showing prescription initiation and escalation within that window corroborate the diagnosis timeline.

[!KEY] The ACR fibromyalgia criteria do not require abnormal imaging or lab results. This means the pharmacy record — showing progressive medication escalation for widespread pain, fatigue, and cognitive symptoms — becomes one of the most important objective documents in the case file.

FDA-Approved Medications for Fibromyalgia

Three medications carry FDA approval specifically for fibromyalgia management:

Pregabalin (Lyrica) — The first FDA-approved fibromyalgia treatment (2007). Pregabalin is a calcium channel alpha-2-delta ligand that reduces central sensitization by decreasing neuronal excitability. Typical dosing ranges from 150 mg to 450 mg per day in divided doses. It addresses pain, sleep disturbance, and fatigue. Pregabalin is controlled (Schedule V), which means the prescribing record provides an additional documentation layer in PI cases.

Duloxetine (Cymbalta) — An SNRI with FDA approval for fibromyalgia (2008) as well as major depressive disorder, generalized anxiety disorder, and diabetic neuropathy. Duloxetine's dual mechanism (serotonin and norepinephrine reuptake inhibition) addresses both the affective and pain-processing components of fibromyalgia. Dosing is typically 60–120 mg/day. In personal injury cases with comorbid depression, duloxetine offers the dual benefit of treating both conditions simultaneously.

Milnacipran (Savella) — The third FDA-approved fibromyalgia medication (2009). Milnacipran is an SNRI with a higher ratio of norepinephrine to serotonin activity compared to duloxetine, which may produce better pain outcomes in some patients. It is not approved for depression in the United States (though it is used for that purpose in Europe). Dosing is 50 mg twice daily, titrated from a lower starting dose.

Off-Label Options Commonly Used in PI Cases

When FDA-approved medications provide incomplete relief — common in post-traumatic fibromyalgia due to the severity and chronicity of the sensitization — physicians add off-label agents:

Low-dose naltrexone (LDN) — At doses of 1.5–4.5 mg/day (far below the opioid-blocking dose of 50 mg), naltrexone appears to modulate glial cell activation and reduce neuroinflammation. Emerging research supports its use in fibromyalgia, and pain management physicians increasingly prescribe it as an adjunct. LDN requires compounding, making the pharmacy lien relationship particularly important.

Low-dose amitriptyline — A tricyclic antidepressant used at 10–75 mg at bedtime specifically for fibromyalgia-related sleep disruption and pain amplification. Amitriptyline is not FDA-approved for fibromyalgia but has decades of evidence supporting its use. At these doses, the primary mechanism is not antidepressant but rather pain modulation and sleep architecture improvement.

Cyclobenzaprine at bedtime — Cyclobenzaprine, a skeletal muscle relaxant structurally related to tricyclics, has been used at low doses (5–10 mg at bedtime) specifically for fibromyalgia-related non-restorative sleep and pain. This is distinct from its daytime use for acute muscle spasm and requires documentation of the specific fibromyalgia rationale.

The Causation Challenge in Personal Injury Cases

Defense counsel and insurers attack post-traumatic fibromyalgia on two fronts:

Causation: "Fibromyalgia is a constitutional condition. The accident didn't cause it — it would have developed anyway." The rebuttal requires expert testimony documenting the claimant's pre-accident health status and the temporal relationship between the injury and symptom onset.

Severity: "The claimant's reports are subjective. There's no objective finding." The rebuttal here is the pharmacy record. A claimant who has been prescribed and filling three fibromyalgia medications — pregabalin, duloxetine, and low-dose amitriptyline — for 18 consecutive months is not malingering. The prescribing rheumatologist's decision to escalate medications documents progressive, treatment-resistant symptomatology.

[!KEY] The pharmacy record is the anti-malingering document. Insurance adjusters and defense attorneys cannot argue that a claimant is exaggerating pain that has required continuous, escalating pharmacotherapy prescribed by a board-certified rheumatologist.

How the Pharmacy Lien Covers the Full Fibromyalgia Regimen

Post-traumatic fibromyalgia treatment is rarely a single-medication situation. Claimants often require:

• A primary FDA-approved agent (pregabalin or duloxetine)
• A sleep/pain adjunct (low-dose amitriptyline or cyclobenzaprine)
• An LDN compound from a compounding pharmacy
• A rescue agent for pain flares

Under a pharmacy lien, LienScripts dispenses all components of this regimen — including compounded medications like LDN — with repayment deferred to case settlement. There are no formulary restrictions, no prior authorization battles, and no treatment gaps.

This continuity matters clinically: fibromyalgia is a condition where treatment interruptions produce significant setbacks, and a claimant who has to go off pregabalin because their insurance denied coverage will experience a measurable worsening documented in the treating physician's notes.

Documenting Fibromyalgia Pharmacotherapy in the Demand Package

For attorneys building the demand:

Timeline correlation: The pharmacy record shows when each medication was initiated. If pregabalin was first prescribed 4 months post-accident and then duloxetine was added at 8 months when pregabalin alone proved insufficient, that escalation timeline corroborates the rheumatologist's notes about progressive sensitization.

Specialist involvement: Fibromyalgia prescriptions from a rheumatologist or pain management specialist carry more weight than primary care prescriptions. The demand should highlight that the claimant required specialist management, not just a GP-level response.

Comorbidity documentation: When the pharmacy record shows concurrent prescriptions for depression (SSRIs), sleep disturbance (amitriptyline, trazodone), and widespread pain (pregabalin, duloxetine), it paints a picture of the full functional impact of the fibromyalgia syndrome on the claimant's quality of life.

Future medication costs: Unlike a fracture, fibromyalgia has no definitive end point. The treating rheumatologist's opinion about the expected duration of pharmacotherapy supports a future medical expense calculation in the demand.

Related Resources

• Gabapentin vs. Pregabalin in Personal Injury Cases
• Low-Dose Naltrexone for Chronic Pain After Personal Injury
• PTSD Medications After Personal Injury
• Cyclobenzaprine vs. Tizanidine: Muscle Relaxants in PI Cases
• Chronic Pain Management After Accident
• Compound Medications in Personal Injury